Depression is a major public health concern that results in a wide range of economic costs to people, their families, and the health care system. Our study sought to determine the direct medical costs incurred by the Ontario government owing to cessation of antidepressant therapy during pregnancy.
Methods:
We conducted an economic evaluation by making assumptions based on data obtained from Statistics Canada, federal and provincial government reports, and relevant depression literature. The analysis included the number of pregnant women with depression residing in Ontario and, subsequently, the number of those women who experienced depressive relapse during pregnancy owing to discontinuation of antidepressant medication. The cost of physician services, hospitalizations, and the birth of preterm and low birth weight infants (2 adverse outcomes associated with untreated depression during pregnancy) were also taken into consideration.
Results:
An estimated 2953 pregnant women with depression in Ontario annually discontinue antidepressant therapy and subsequently have a depressive relapse. An estimated $20 546 982 is spent annually in Ontario on untreated maternal depression in pregnancy; this is the total after subtracting the cost of risks associated with treated depression during pregnancy ($3 144 053).
Conclusions:
Safe treatment options for the management of depression during pregnancy should be actively explored as treated depression translates into cost savings for the Ontario government and society as a whole. Beyond this cost, depression interferes with the quality of childrearing, maternal responsiveness to infants, and other determinants essential for optimal child development.
Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001;46(Suppl 1):5S–90S.
3.
Canadian Institute for Health Information. Exploring the 70/30 split: How Canada's health care system is financed [Internet]. Ottawa (ON): CIHI; 2005 [cited 2008 Jan 25]. Available from: http://secure.cihi.ca/cihiweb/products/FundRep_EN.pdf.
4.
MacqueenGChokkaP.Special issues in the management of depression in women. Can J Psychiatry. 2004;49(Suppl 1):27S–40S.
5.
WeissmanMMOlfsonM.Depression in women: Implications for health care research. Science. 1995;269:799–801.
6.
WisnerKLGelenbergAJLeonardH, Pharmacologic treatment of depression during pregnancy. JAMA. 1999;282:1264–1269.
7.
GoldLH. Clinical and forensic aspects of postpartum disorders. J Am Acad Psychiatry Law. 2001;29:344–347.
8.
BurtVKSteinK.Epidemiology of depression throughout the female life cycle. J Clin Psychiatry. 2002;63(Suppl 7):9–15.
9.
NonacsRCohenLS. Assessment and treatment of depression during pregnancy: An update. Psychiatr Clin North Am. 2003;26:547–562.
10.
KaplanEM. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry. 1997;58(Suppl 7):31–35.
11.
CohenLSAltshulerLLHarlowBL, Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499–507.
12.
GoldLH. Psychopharmacologic treatment of depression during pregnancy. Curr Womens Health Rep. 2003;3:236–241.
13.
ZuckermanBAmaroHBauchnerH, Depressive symptoms during pregnancy: Relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160:1107–1111.
14.
BonariLPintoNAhnE, Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49:726–735.
15.
BrentRLBeckmanDA. Environmental teratogens. Bull NY Acad Med. 1990;66:123–163.
16.
EinarsonTREinarsonA.Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14:823–827.
17.
ChambersCDHernandez-DiazSVan MarterLJ, Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–587.
18.
ShahCP. Public health and preventive medicine in Canada. Toronto (ON): University of Toronto Press; 1998.
BennettHAEinarsonATaddioA, Prevalence of depression during pregnancy: Systematic review. Obstet Gynecol. 2004;103:698–709.
24.
PirragliaPStaffordRSingerD.Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003;5(4):153–157.
25.
LinEHVon KorffMKatonW, The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67–74.
26.
EinarsonASelbyPKorenG.Abrupt discontinuation of psychotropic drugs during pregnancy: Fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001;26:44–48.
27.
BonariLKorenGEinarsonTR, Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8:214–220.
28.
KoopmansGTDonkerMCRuttenFH. Common mental disorders and use of general health services: A review of the literature on population-based studies. Acta Psychiatr Scand. 2005;111:341–350.
29.
LinEGoeringP.The utilization of physician services for mental health in Ontario. Toronto (ON): Institute for Clinical Evaluative Sciences; 1999.
30.
ChanBTBSchultzSE. Supply and utilization of general practitioner and family physician services in Ontario. Toronto (ON): Institute for Clinical Evaluative Sciences; 2005. [Investigative Report].
31.
WatsonDEHeppnerPRoosNP, Population-based use of mental health services and patterns of delivery among family physicians, 1992 to 2001. Can J Psychiatry. 2005;50:398–406.
32.
Public Health Agency of Canada. A report on mental illnesses in Canada: October 2002 [Internet]. Ottawa (ON): Health Canada; 2002 [cited 2008 Jan 25]. Available from: http://www.phac-aspc.gc.ca/publicat/miic-mmac/.
33.
ChungTKLauTKYipAS, Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001;63:830–834.
34.
BerkowitzGSPapiernikE.Epidemiology of preterm birth. Epidemiol Rev. 1993;15:414–443.
35.
HalbreichU.The association between pregnancy processes, preterm delivery, low birth weight, and postpartum depressions—the need for interdisciplinary integration. Am J Obstet Gynecol. 2005;193:1312–1322.
36.
OrrSTJamesSABlackmorePC. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol. 2002;156:797–802.
37.
PetrouS.The economic consequences of preterm birth during the first 10 years of life. BJOG. 2005;112(Suppl 1):10–15.
38.
SchmittSKSneedLPhibbsCS. Costs of newborn care in California: A population-based study. Pediatrics. 2006;117:154–160.
39.
LewitEMBakerLSCormanH, The direct cost of low birth weight. Future Child. 1995;5:35–56.
40.
US Environmental Protection Agency—Office of Pollution Prevention and Toxics. Cost of low birth weight. In: US Environmental Protection Agency—Office of Pollution. Cost of illness handbook. [place unknown]: United States Environmental Protection Agency; 2006. Chapter 2.
41.
BoulengerSNixonJDrummondM, Can economic evaluations be made more transferable?Eur J Health Econ. 2005;6:334–346.
42.
KhawamEALaurencicGMaloneDAJr., Side effects of antidepressants: An overview. Cleve Clin J Med. 2006;73:351–361.
43.
YuanYTsoiKHuntRH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: Confusion or confounding?Am J Med. 2006;119:719–727.
44.
PacherPKecskemetiV.Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns?Curr Pharm Des. 2004;10:2463–2475.
45.
MackayFJDunnNRMannRD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–874.
46.
Moses-KolkoELBogenDPerelJ, Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA. 2005;293:2372–2383.
47.
KorenGMatsuiDEinarsonA, Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?CMAJ. 2005;172:1457–1459.
48.
GafniAGoereeRMyhrTL, Induction of labour versus expectant management for prelabour rupture of the membranes at term: An economic evaluation. TERMPROM Study Group. Term Prelabour Rupture of the Membranes. CMAJ. 1997;157:1519–1525.
MarcusSMFlynnHABlowFC, Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt). 2003;12:373–380.
51.
MinkovitzCSStrobinoDScharfsteinD, Maternal depressive symptoms and children's receipt of health care in the first 3 years of life. Pediatrics. 2005;115:306–314.
52.
ChambersCDJohnsonKADickLM, Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015.
53.
AddisAKorenG.Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychol Med. 2000;30:89–94.
54.
KulinNAPastuszakASageSR, Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA. 1998;279:609–610.
55.
EinarsonAFatoyeBSarkarM, Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry2001;158:1728–1730.
56.
EinarsonABonariLVoyer-LavigneS, A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003;48:106–110.
57.
Chun-Fai-ChanBKorenGFayezI, Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol. 2005;192:932–936.
58.
DjulusJKorenGEinarsonTR, Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry. 2006;67:1280–1284.
